Add to Favourites
To login click here
Owkin, a TechBio company, has chosen Amazon Web Services (AWS) as its primary cloud provider to develop generative AI applications and accelerate drug discovery and development. By leveraging AWS’s secure and scalable cloud infrastructure, Owkin aims to enhance data operations and drive research in precision medicine. The collaboration between Owkin and AWS will also accelerate innovation in biotech through the use of high-performance computing and machine learning tools.